Search Results
Jul 22, 2026, 16:05 ET Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
conference call, participants can dial +1 833-461-5787 (U.S. toll-free) and enter access code 762246460. An archived recording will be available on Nuvation Bio's website for 90 days following the event.About Nuvation Bio Nuvation Bio is a global oncology company focused on tackling some
More news about: Nuvation Bio, Inc.
Jul 22, 2026, 09:00 ET Formation Bio Appoints Michael Ehlers as Chief Scientific Officer and Head of R&D
portfolio strategy and advancement, from translational sciences through clinical development. He will also guide the scientific direction of Formation Bio's AI platform.
More news about: Formation Bio
Jul 22, 2026, 08:00 ET Kirin Group and Blackmores to Launch New Cognizin® Cognitive Support Supplements in Australia and New Zealand
across the Asia-Pacific region by combining Blackmores' consumer insights, trusted brand presence, and product development capabilities with Kyowa Hakko Bio's expertise in scientifically supported ingredients.Cognitive function plays an important role in quality of life, supporting memory, attention,
More news about: Kyowa Hakko U.S.A
Jul 22, 2026, 07:45 ET Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway
Ministry of Health Accepts Entolimod for Formal Review — Following its request for submission, Ukraine's Ministry of Health has accepted Valion Bio's Entolimod regulatory dossier for formal review under the country's Regulatory Equivalence Pathway, initiating the Ministry's scientific and regulatory
More news about: Valion Bio, Inc.
Jul 22, 2026, 07:00 ET Cizzle Bio Launches CIZ1B Biomarker Blood Test for Early Lung Cancer
laboratory validation at OmniHealth Diagnostics, is now being offered through the Dallas-based CLIA-certified laboratory as the first phase of Cizzle Bio's U.S. commercialization strategy. The company expects to expand physician access in the coming months through additional CLIA-certified laboratory partners
More news about: Cizzle Bio
Jul 21, 2026, 09:39 ET Immorta Bio and Collaborators Publish Blueprint for the Future of AI-Driven Precision Medicine
Medicine's leadership in advancing precision healthcare, and Immorta Bio's focus on translating advances in aging biology into innovative therapeutics.The concepts described in this publication closely align with Immorta Bio's long-term strategy of integrating artificial intelligence, computational
More news about: Immorta Bio Inc.
Jul 21, 2026, 08:13 ET Wheeler Bio Appoints Rajesh Beri, Ph.D., as Chief Development Officer
Development Officer, Dr. Beri will lead Wheeler Bio's development organization, supporting integrated CMC programs from cell line development through Drug Substance and Drug Product manufacturing. He will oversee the scientific strategy supporting Wheeler Bio's signature ModularCMC® platform, with an eye
More news about: Wheeler Bio, Inc.
Jul 21, 2026, 08:00 ET Dynabook Launches the Portégé X30L-P, Delivering Premium Performance in an Ultra-Light 13.3-Inch Business Laptop
laptop helps protect against advanced security threats with a secure combination of hardware, firmware and software protections. Dynabook's proprietary BIOS provides a trusted foundation, while biometric authentication options, including fingerprint and facial recognition, help support fast and secure access.
More news about: Dynabook Americas, Inc.
Jul 20, 2026, 13:28 ET World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market
Sheba Medical Center, which is ranked the #7 hospital in the world, has chosen to evaluate and fund a trial of Valion Bio's Entolimod in cancer patients, creating a second clinical development pathway beyond Acute Radiation Syndrome.
More news about: Valion Bio, Inc.
Jul 20, 2026, 08:10 ET Consano Bio Receives FDA Investigational New Drug Clearance to Expand the C-1101 Chronic Sciatica Clinical Development Program into the United States
The IND clearance authorizes expansion of Consano Bio's ongoing Phase 1 clinical trial to include U.S. clinical sites, complementing the study currently underway in Australia. The multi-center, randomized,
More news about: Consano Bio
Jul 20, 2026, 08:00 ET Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE® by
More news about: Halozyme Therapeutics, Inc.
Jul 20, 2026, 08:00 ET Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
by evaluating the potential role of safusidenib in patients who have progressed on prior targeted therapy."These studies build upon Nuvation Bio's safusidenib clinical development program, which includes the currently enrolling pivotal Phase 3 SIGMA study, evaluating safusidenib compared to placebo as a
More news about: Nuvation Bio Inc.
Jul 16, 2026, 12:00 ET Illumina expands Billion Cell Atlas program with new AI drug developers
healthy cell types can reveal how diseases originate and develop, as well as how we may be able to reverse their progression."Formation Bio's model is to identify and acquire promising medicines already close to or in the clinic, then use AI and technology to develop them faster and more efficiently.
More news about: Illumina, Inc.
Jul 16, 2026, 09:14 ET Juno Bio Opens First CLIA-Certified Sequencing Lab Dedicated Entirely to Women's Health, Backed by Ada Ventures, Artesian, Illumina Accelerator, and Entrepreneur First
approaches."Juno Bio's new clinically actionable vaginal microbiome and STI test is designed to address a critical gap in women's health, where recurrent infections, fertility concerns, and peri- and menopausal symptoms are frequently misunderstood or inadequately treated. Processed in Juno Bio's own CLIA-certified
More news about: Juno Bio
Jul 15, 2026, 16:12 ET New Impeachment Symposium to Feature Members of Congress, Legal Scholars, Leading Experts and Activists
https://nader.org/impeachment-symposium-july-2026-agenda-and-bios/ FOR MORE INFORMATION, CONTACT:Ralph Nader or Bruce FeinPhone: 202-387-8030Email:
More news about: Ralph Nader, Consumer Advocate
Jul 15, 2026, 10:31 ET Soft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsight
Letetresgene autoleucel (US WorldMeds), Risvutatug rezetecan (GSK), Tigilanol Tiglate (QBiotics Group), and others.Takara Bio's TBI-1301 (mipetresgene autoleucel) is an investigational autologous T-cell receptor-engineered (TCR-T) cell therapy being developed by Takara Bio
More news about: DelveInsight Business Research, LLP
Jul 15, 2026, 09:03 ET Legrand Introduces Next-Generation KVM Platform Built to Bring Critical Systems Back Online in Minutes
remote access becomes critical during outages or cyber-related disruptions. Because KVM works below the operating system layer, technicians can reach BIOS settings, restart systems into safe mode and begin recovery remotely. In many cases, this helps IT teams cut Mean Time to Recovery (MTTR) from days
More news about: Legrand DPC LLC
Jul 15, 2026, 09:00 ET Primrose Bio Awarded NIH Grant to Develop Genetic Medicine Drug Design Technology
builds upon foundational research into sequence design elements that significantly improved protein expression."This award builds on Primrose Bio's track record of bringing enabling technologies into commercial use," said Drew Burch, Chief Executive Officer of Primrose Bio. "It expands the sequence-based
More news about: Primrose Bio
Jul 15, 2026, 09:00 ET Cellular Intelligence Expands Leadership Team with Seasoned AI and Biotech Industry Executives
of Form Bio, the genome engineering and genetic medicine platform spun out of Colossal Biosciences, the de-extinction company, where he built Form Bio's brand, market positioning, and go-to-market engine. Earlier, he served as chief marketing officer of Invoiced, acquired by Flywire in 2024, and in various
More news about: Cellular Intelligence
Jul 14, 2026, 22:58 ET Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
are not limited to, risks and uncertainties related to the risk that additional data, or the results of ongoing data analyses, may not support Q32 Bio's current beliefs and expectations for bempikibart, including with respect to the durability of clinical responses, the risk that ongoing and future clinical
More news about: Q32 Bio
Jul 14, 2026, 09:30 ET RainFocus Integrations with Adobe Automate Event Data Sync and Centralize Brand Assets
Manager?RainFocus syncs with Adobe Experience Manager through a native connector that maps event data fields (like session titles or speaker bios) to Adobe Experience Manager content fragments. Additionally, the Content Advisor allows users to browse and embed Adobe Experience Manager assets directly
More news about: RainFocus
Jul 14, 2026, 07:45 ET Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
use in oncology supportive care and other immunomodulatory applications.Why It MattersThese developments support Valion Bio's broader strategy to build an integrated biotechnology platform around a common scientific and manufacturing foundation:Government
More news about: Valion Bio, Inc.
Jul 13, 2026, 16:01 ET Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
are not limited to, risks and uncertainties related to the risk that additional data, or the results of ongoing data analyses, may not support Q32 Bio's current beliefs and expectations for bempikibart, including with respect to the durability of clinical responses, the risk that ongoing and future clinical
More news about: Q32 Bio
Jul 13, 2026, 08:35 ET A Longhorn in Dallas Has Been Calling the Knockout Rounds All Tournament. On Thursday, He Picks the Winner of the Final. Live.
arrive from 6:30 PM; the pick happens at 7:30 PM on the dot. Admission is free, by approved RSVP only, through the Partiful link in the @drizz.drops bios. The guest list prioritizes journalists, creators, and visiting soccer fans."I grew up between Dallas and Mexico City, and this summer both of
More news about: Drizz
Jul 13, 2026, 06:59 ET Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
www.Q32Bio.com, including, but not limited to, Q32 Bio's disclosures, investor presentations and FAQs, Securities and Exchange Commission (the "SEC") filings, press releases, public conference call transcripts
More news about: Q32 Bio